Hepatitis C treatment for injection drug users: a review of the available evidence.
about
Dihydrocodeine for detoxification and maintenance treatment in illicit opiate-dependent individualsBarriers to hepatitis C treatmentHepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationTreatment of hepatitis C as prevention: a modeling case study in VietnamCorrelates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunityEligibility of persons who inject drugs for treatment of hepatitis C virus infection.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR.Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Ending hepatitis C in the United States: the role of screening.Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region.Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond?Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidenceAssessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral HepatitisHepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionEpidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.Identification of hepatitis C virus transmission using a next-generation sequencing approach.Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.The high comorbidity burden of the hepatitis C virus infected population in the United States.Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findingsConcurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levelsHepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.
P2860
Q26471618-87ABE945-68ED-46AB-B4A2-5D6CFDB313C1Q27012664-8AD4A3F1-6D5C-44E6-B3B4-CB4C1C88D1F3Q27014761-69A1C5FB-3C8A-4C63-AEC1-70003972C6B4Q28079102-909B6EDE-CF6F-4CAF-BC48-4C31DCC317C9Q28482272-DEE62901-488B-4F85-A054-49334B846C7AQ28546457-FAB9125B-5220-484D-AEF7-8C5938EDF864Q28741305-B67A3210-4B51-4EC5-8C4D-2EF64A60DD24Q30429470-0A845E5B-1AAE-4065-BF6A-02658C5B6B01Q30453975-E01866E0-6C88-46B0-A88F-D1ADA27F2A47Q33626887-3A1289E0-6E0F-4DD7-AF43-BF372B611DA5Q33821728-BD21B603-AE6C-4FB6-9D32-2E1D52365F0FQ33853664-8FDA27A4-B93A-4993-BA1B-61844FE2F40DQ33862919-CE80B646-C7B0-4EB0-90B0-E246ABBF6BB0Q33878388-B37C1EA8-B28C-4101-9FB1-57B5796BEC21Q34073122-B1F3D1CE-27CA-4CBF-93A6-EADF6EE8E466Q34115061-28B41B99-A96D-422F-92CA-38EBDEEF51F5Q34260584-060BE341-141D-4282-A532-CB1317A9B7B1Q34260649-68EFAB67-A984-418B-ADF6-1F1D566DBCB5Q34417838-F3D3B51A-ADFD-4046-8755-262FE686DA36Q34825751-2459D223-BF53-4DBE-A094-29EA66B8BB7DQ35053344-4F9E7167-5D07-4DCC-B5F7-7F3654CE012EQ35074238-B817B476-3199-4153-A27F-2D96C12A0EBCQ35535844-564AF4C0-0154-43AE-A5BB-C3D712ACDBB5Q35540200-132C0E9C-9CF1-4159-A033-120165315525Q35565944-B1986B25-EB45-411B-83A6-F46D06FD7B7EQ35764220-693EDEA3-1B47-4023-874E-58083CDE0A14Q35846408-DF0E20B4-7A91-4650-BD60-6C00A885A183Q35865346-6207A12C-7BB6-47D1-B06A-CE2DAC1101A7Q35867817-707FD1CA-F69C-46A9-823E-C5812E03D01FQ35903305-350FABAE-DE2B-4DF5-BB7C-149DD3EAC241Q35927970-F4539C07-D1DA-4D47-A257-9BE251555023Q35961748-944765ED-C911-467E-977F-2A6F6F9706DCQ36063808-A665E783-64A6-436C-8203-CEA67C1AC6D2Q36079786-427D6BA6-6DDE-4FA3-B6E1-21B93E009CA4Q36079814-7366AF3B-75FB-48A7-BE00-4716981D3B85Q36123087-841E9DA4-2FB7-49F7-A772-EFB739ECBC0BQ36263653-9318ACBE-EE21-4F6A-AA11-FDEE803797D1Q36421892-5EEA7DAC-8E48-40B0-AA09-647FFAA5F540Q36590782-BD7F45BF-9B63-4443-8B46-89526D58D6ACQ36607811-38E45147-7439-4544-A4D4-C5358C2824F3
P2860
Hepatitis C treatment for injection drug users: a review of the available evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis C treatment for injection drug users: a review of the available evidence.
@en
Hepatitis C treatment for injection drug users: a review of the available evidence.
@nl
type
label
Hepatitis C treatment for injection drug users: a review of the available evidence.
@en
Hepatitis C treatment for injection drug users: a review of the available evidence.
@nl
prefLabel
Hepatitis C treatment for injection drug users: a review of the available evidence.
@en
Hepatitis C treatment for injection drug users: a review of the available evidence.
@nl
P356
P1476
Hepatitis C treatment for injection drug users: a review of the available evidence.
@en
P2093
Margaret Hellard
P304
P356
10.1086/600304
P407
P577
2009-08-01T00:00:00Z